Bio-Rad Laboratories, Inc. (BIO) | Investment Case

1. Company Snapshot

1.a. Company Description

Bio-Rad Laboratories, Inc.manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.The company operates through Life Science and Clinical Diagnostics segments.

The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety.This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories.

The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market.This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market.It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories.

In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers.Bio-Rad Laboratories, Inc.

was founded in 1952 and is headquartered in Hercules, California.

Show Full description

1.b. Last Insights on BIO

Bio-Rad Laboratories' recent performance was negatively impacted by its Q4 earnings miss, with EPS of $2.51 per share falling short of the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. Margins shrank, contributing to the shortfall. Despite revenue growth and a rebound in Clinical Diagnostics sales, shares slid 12%. The company's consensus recommendation is "Hold" from six research firms, with one analyst rating it a sell and two issuing a hold recommendation.

1.c. Company Highlights

Last Price	267.85
Change Percentage	-1.32%
Open	271.25
Previous Close	271.44
Market Cap ( Millions)	7229
Volume	175856
Year High	343.12
Year Low	211.43
M A 50	295.17
M A 200	284.56

FCF Yield	5.18%
Dividend Yield	0.00%
ROE	10.86%
Debt / Equity	20.54%
Net Debt / EBIDTA	118.16%
Price To Book	0.97
Price Earnings Ratio	9.51
Price To FCF	19.3
Price To sales	2.8
EV / EBITDA	9.73

2. Bio-Rad's Q4 2025 Earnings: A Mixed Bag

Bio-Rad's fourth quarter 2025 revenue was $693 million, a 3.9% increase from Q4 2024, or 1.7% on a currency-neutral basis. The company's non-GAAP gross margin was 53.3%, down from 55% in 2024, and non-GAAP operating margin was 12.1%. Non-GAAP net income was $271 million or $9.92 diluted earnings per share. Actual EPS came out at $2.51, slightly lower than estimates of $2.57. For the full year 2025, net sales were $2.583 billion, a 0.7% increase from 2024.

Publication Date: Feb -16

                                    📋 Highlights
                                    Q4 2025 Revenue Growth::
                                                Rose to $693M (+3.9 YoY), with Clinical Diagnostics up 8.4% driven by quality control and blood typing sales.
Life Science Segment Decline::
                                                Sales fell 2.6% due to constrained academic research and biotech funding.
Full-Year 2025 Sales::
                                                Reached $2.583B (+0.7 YoY), with non-GAAP gross margin dropping to 53.3% from 55%.
ddPCR Portfolio Momentum::
                                                Mid-single-digit growth from QX700 platform, with guidance for sustained mid-single-digit expansion from consumables.
2026 Guidance::
                                                Revenue growth of 0.5–1.5% (currency-neutral), free cash flow of $375–395M, and EBIT margin of 12–12.5% despite Process Chromatography margin headwinds.

                                

Segment Performance

The Clinical Diagnostics segment grew 8.4% on a reported basis, driven by higher sales of quality control and blood typing products. In contrast, the Life Science segment sales declined 2.6% on a reported basis, due to constrained academic research and biotech funding. The ddPCR portfolio posted mid-single-digit year-over-year growth, driven by the QX700 platform. As the company noted, "the ddPCR business saw strong quarterly growth, driven by the QX700 platform, with a large installed base and a shift from qPCR applications to ddPCR."

Guidance and Outlook

Guidance for 2026 includes currency-neutral revenue growth of 0.5% to 1.5%, with Life Science segment growth of 0 to 0.5% and Diagnostics segment growth of 1% to 2%. Non-GAAP gross margin is projected to be 54% to 54.5%, and non-GAAP operating margin is expected to be 12% to 12.5%. The company expects full-year free cash flow of $375 million to $395 million. Analysts estimate next year's revenue growth at 3.5%, indicating a potential upside.

Valuation and Metrics

With a P/E Ratio of 9.11 and an EV/EBITDA of 26.31, the stock appears to be reasonably valued. The company's Free Cash Flow Yield is 3.69%, indicating a decent return for investors. The ROE is 10.86%, suggesting a relatively healthy return on equity. However, the Net Debt / EBITDA ratio is 2.33, indicating a moderate level of debt.

Operational Highlights

The company expects continued actions around operational rigor, simplification, and prioritization. The Process Chromatography business faces a short-term impact due to changed vaccine production expectations and efficiencies, resulting in a 50-basis-point headwind to op margin. The ddPCR platform offers strong margin products, with potential for margin enhancement. The company aims to drive durable changes and is moving thoughtfully to ensure these changes are sustainable.

3. NewsRoom

Fisher Asset Management LLC Lowers Stock Position in Bio-Rad Laboratories, Inc. $BIO

Mar -04

Source: defenseworld.net

Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients

Mar -03

Source: globenewswire.com

FibroBiologics to Present at the BIO Investment & Growth Summit

Feb -26

Source: globenewswire.com

International Markets and Bio-Rad (BIO): A Deep Dive for Investors

Feb -20

Source: zacks.com

Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down

Feb -19

Source: zacks.com

Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of “Hold” by Brokerages

Feb -19

Source: defenseworld.net

Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Feb -13

Source: seekingalpha.com

Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates

Feb -12

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.63%)

6. Segments

Clinical Diagnostics

Expected Growth: 3.5%

Bio-Rad Laboratories' Clinical Diagnostics segment growth of 3.5% is driven by increasing demand for infectious disease testing, expansion in emerging markets, and adoption of digital PCR technology. Additionally, the company's strategic acquisitions and investments in product development have enhanced its portfolio, contributing to revenue growth.

Life Science

Expected Growth: 3.8%

Bio-Rad Laboratories, Inc.'s Life Science segment growth of 3.8% is driven by increasing demand for genomic research, proteomics, and cell biology products. The rise of precision medicine, gene editing, and COVID-19 research also contribute to growth. Additionally, the company's investments in digital PCR and Droplet Digital PCR technologies, as well as its expanding presence in emerging markets, support segment growth.

Other

Expected Growth: 3.2%

Bio-Rad Laboratories' 3.2% growth in 'Other' segment is driven by increasing demand for its digital biology and synthetic biology products, expansion into new geographies, and strategic partnerships. Additionally, the company's focus on innovation and R&D investments in emerging technologies such as CRISPR and gene editing are contributing to growth.

7. Detailed Products

PCR (Polymerase Chain Reaction) Instruments

Bio-Rad's PCR instruments are designed for amplifying specific DNA sequences, enabling researchers to analyze and detect genetic material.

Real-Time PCR Systems

Bio-Rad's real-time PCR systems provide accurate and sensitive detection of nucleic acids, enabling researchers to quantify and analyze gene expression.

Droplet Digital PCR Systems

Bio-Rad's droplet digital PCR systems enable precise and sensitive detection of nucleic acids, allowing researchers to analyze rare mutations and genetic variations.

Protein Purification and Analysis

Bio-Rad's protein purification and analysis products enable researchers to isolate, purify, and analyze proteins, facilitating the study of protein function and structure.

Western Blotting and Imaging

Bio-Rad's western blotting and imaging products enable researchers to analyze protein expression and modification, facilitating the study of protein function and disease mechanisms.

Cell Isolation and Analysis

Bio-Rad's cell isolation and analysis products enable researchers to isolate, analyze, and characterize cells, facilitating the study of cell biology and disease mechanisms.

Food Safety Testing

Bio-Rad's food safety testing products enable the detection of pathogens, toxins, and other contaminants in food, ensuring a safe food supply.

Quality Control and Process Validation

Bio-Rad's quality control and process validation products enable the development and validation of diagnostic tests, ensuring the accuracy and reliability of test results.

8. Bio-Rad Laboratories, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bio-Rad Laboratories, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing development of new technologies and products.

Bargaining Power Of Customers

Bio-Rad Laboratories, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Bio-Rad Laboratories, Inc. relies on a network of suppliers for raw materials and components. While the company has some bargaining power due to its size, suppliers may still have some leverage due to the specialized nature of the products.

Threat Of New Entrants

The life science research and clinical diagnostics markets are highly regulated, and new entrants would need to invest heavily in research and development, manufacturing, and regulatory compliance to compete with Bio-Rad Laboratories, Inc.

Intensity Of Rivalry

The life science research and clinical diagnostics markets are highly competitive, with several established players competing for market share. Bio-Rad Laboratories, Inc. faces intense competition from companies such as Thermo Fisher Scientific, Inc. and Danaher Corporation.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	12.34%
Debt Cost	4.69%
Equity Weight	87.66%
Equity Cost	8.63%
WACC	8.15%
Leverage	14.08%

11. Quality Control: Bio-Rad Laboratories, Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Insulet

A-Score: 5.3/10

Value: 0.2

Growth: 9.6

Quality: 7.9

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

CONMED

A-Score: 4.8/10

Value: 7.4

Growth: 6.4

Quality: 5.9

Yield: 3.0

Momentum: 1.0

Volatility: 5.0

1-Year Total Return ->

Inari Medical

A-Score: 4.8/10

Value: 4.0

Growth: 8.0

Quality: 4.8

Yield: 0.0

Momentum: 9.5

Volatility: 2.3

1-Year Total Return ->

iRhythm Technologies

A-Score: 4.7/10

Value: 4.2

Growth: 6.1

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

Bio-Rad

A-Score: 4.0/10

Value: 6.5

Growth: 2.3

Quality: 4.7

Yield: 0.0

Momentum: 5.0

Volatility: 5.3

1-Year Total Return ->

Integra LifeSciences

A-Score: 3.0/10

Value: 8.3

Growth: 2.3

Quality: 4.1

Yield: 0.0

Momentum: 0.5

Volatility: 3.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

4.77%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

8.15%

Bio-Rad Laboratories, Inc. - US0905722072

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on BIO

1.c. Company Highlights

Less Volatile

Fairly Valued

Stable Momentum

Earnings Beats

Revenues Miss

Average Growth

Revenues Beats

Average Yield

Average Quality

Medium Volatility

Expensive

Lower Growth

Earnings Miss

2. Bio-Rad's Q4 2025 Earnings: A Mixed Bag

Segment Performance

Guidance and Outlook

Valuation and Metrics

Operational Highlights

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.63%)

6. Segments

Clinical Diagnostics

Expected Growth: 3.5%

Life Science

Expected Growth: 3.8%

Other

Expected Growth: 3.2%

7. Detailed Products

PCR (Polymerase Chain Reaction) Instruments

Real-Time PCR Systems

Droplet Digital PCR Systems

Protein Purification and Analysis

Western Blotting and Imaging

Cell Isolation and Analysis

Food Safety Testing

Quality Control and Process Validation

8. Bio-Rad Laboratories, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Bio-Rad Laboratories, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

267.85$

Current Price

267.85$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA